{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,5]],"date-time":"2026-01-05T22:06:32Z","timestamp":1767650792376,"version":"3.37.3"},"reference-count":8,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,3,20]],"date-time":"2021-03-20T00:00:00Z","timestamp":1616198400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2021,3,20]],"date-time":"2021-03-20T00:00:00Z","timestamp":1616198400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100000024","name":"Canadian Institutes of Health Research","doi-asserted-by":"publisher","award":["Foundation Grant FDN-167281"],"award-info":[{"award-number":["Foundation Grant FDN-167281"]}],"id":[{"id":"10.13039\/501100000024","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100013220","name":"Ultragenyx Pharmaceutical","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100013220","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000196","name":"Canada Foundation for Innovation","doi-asserted-by":"publisher","award":["CFI-JELF 38412"],"award-info":[{"award-number":["CFI-JELF 38412"]}],"id":[{"id":"10.13039\/501100000196","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Canadian Institutes of Health Research and Muscular Dystrophy Canada","award":["(Network Catalyst Grant for NMD4C"],"award-info":[{"award-number":["(Network Catalyst Grant for NMD4C"]}]},{"DOI":"10.13039\/501100001804","name":"Canada Research Chairs program","doi-asserted-by":"crossref","award":["950-232279"],"award-info":[{"award-number":["950-232279"]}],"id":[{"id":"10.13039\/501100001804","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Orphanet J Rare Dis"],"published-print":{"date-parts":[[2021,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>It has recently been suggested that registries for rare neuromuscular diseases should be formed and governed exclusively by physicians and patients in an effort to limit conflicts of interest. Enacting such an approach would not only be challenging logistically and financially, but it would also exclude the involvement of sponsors, who are an integral component of drug development within the current compliance framework. Therefore, as an alternative to traditional registries, we propose the use of a better collaborative model for post-marketing follow-up that includes all stakeholders. We developed the concept of\u00a0Disease Monitoring Programs (DMPs), which are designed to monitor disease manifestations over a 10-year period whether on a sponsored drug or not, and ensure consistent collection, ownership sharing and governance of data.<\/jats:p>","DOI":"10.1186\/s13023-021-01687-7","type":"journal-article","created":{"date-parts":[[2021,3,20]],"date-time":"2021-03-20T12:02:54Z","timestamp":1616241774000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Disease monitoring programs of rare genetic diseases: transparent data sharing between academic and commercial stakeholders"],"prefix":"10.1186","volume":"16","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2324-8001","authenticated-orcid":false,"given":"Hanns","family":"Lochm\u00fcller","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Antonio Nino","family":"Ramirez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Emil","family":"Kakkis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2021,3,20]]},"reference":[{"key":"1687_CR1","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1186\/s13023-020-01519-0","volume":"15","author":"CEM Hollak","year":"2020","unstructured":"Hollak CEM, Sirrs S, van den Berg S, van der Wel V, Langeveld M, Dekker H, et al. Registries for orphan drugs: generating evidence or marketing tools? Orphanet J Rare Dis. 2020;15:235.","journal-title":"Orphanet J Rare Dis"},{"key":"1687_CR2","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1038\/ejhg.2016.137","volume":"25","author":"H Lochm\u00fcller","year":"2017","unstructured":"Lochm\u00fcller H, Le Cam Y, Jonker AH, Lau LP, Baynam G, Kaufmann P, et al. \u201cIRDiRC Recognized Resources\u201d: a new mechanism to support scientists to conduct efficient, high-quality research for rare diseases. Eur J Hum Genet. 2017;25:162\u20135.","journal-title":"Eur J Hum Genet"},{"key":"1687_CR3","doi-asserted-by":"publisher","first-page":"1293","DOI":"10.1038\/s41431-017-0008-z","volume":"25","author":"H Lochm\u00fcller","year":"2017","unstructured":"Lochm\u00fcller H, Torrent IFJ, Le Cam Y, Jonker AH, Lau LP, Baynam G, et al. The International Rare Diseases Research Consortium: policies and guidelines to maximize impact. Eur J Hum Genet. 2017;25:1293\u2013302.","journal-title":"Eur J Hum Genet"},{"key":"1687_CR4","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1016\/j.nmd.2017.11.001","volume":"28","author":"O Pogoryelova","year":"2018","unstructured":"Pogoryelova O, Cammish P, Mansbach H, Argov Z, Nishino I, Skrinar A, et al. Phenotypic stratification and genotype-phenotype correlation in a heterogeneous, international cohort of GNE myopathy patients: First report from the GNE myopathy Disease Monitoring Program, registry portion. Neuromuscul Disord. 2018;28:158\u201368.","journal-title":"Neuromuscul Disord"},{"key":"1687_CR5","doi-asserted-by":"crossref","unstructured":"Lochm\u00fcller H,Behin A, Tournev I, Tarnopolsky M, Horv\u00e1th R, Pogoryelova O et al. Results from a 3-year non-interventional, observational disease monitoring program in adults with GNE myopathy. Submitted 2020 (under review).","DOI":"10.3233\/JND-200565"},{"key":"1687_CR6","doi-asserted-by":"publisher","first-page":"53","DOI":"10.3233\/JND-200538","volume":"8","author":"V Hodgkinson","year":"2020","unstructured":"Hodgkinson V, Lounsberry J, M'Dahoma S, Russell A, Benstead T, Brais B, et al. The Canadian Neuromuscular Disease Registry 2010\u20132019: a decade of facilitating clinical research through a nationwide, pan-neuromuscular disease registry. J Neuromuscul Dis. 2020;8:53\u201361.","journal-title":"J Neuromuscul Dis."},{"key":"1687_CR7","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1186\/s13023-019-0998-4","volume":"14","author":"A Pechmann","year":"2019","unstructured":"Pechmann A, Konig K, Bernert G, Schachtrup K, Schara U, Schorling D, et al. SMArtCARE\u2014a platform to collect real-life outcome data of patients with spinal muscular atrophy. Orphanet J Rare Dis. 2019;14:18.","journal-title":"Orphanet J Rare Dis"},{"key":"1687_CR8","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1007\/978-3-319-67144-4_5","volume":"1031","author":"R Thompson","year":"2017","unstructured":"Thompson R, Robertson A, Lochmuller H. Natural history, trial readiness and gene discovery: advances in patient registries for neuromuscular disease. Adv Exp Med Biol. 2017;1031:97\u2013124.","journal-title":"Adv Exp Med Biol"}],"container-title":["Orphanet Journal of Rare Diseases"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13023-021-01687-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s13023-021-01687-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13023-021-01687-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,3,20]],"date-time":"2021-03-20T12:05:18Z","timestamp":1616241918000},"score":1,"resource":{"primary":{"URL":"https:\/\/ojrd.biomedcentral.com\/articles\/10.1186\/s13023-021-01687-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,3,20]]},"references-count":8,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["1687"],"URL":"https:\/\/doi.org\/10.1186\/s13023-021-01687-7","relation":{},"ISSN":["1750-1172"],"issn-type":[{"type":"electronic","value":"1750-1172"}],"subject":[],"published":{"date-parts":[[2021,3,20]]},"assertion":[{"value":"23 October 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 January 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 March 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Not applicable.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"HL\u2014Consultancy and financial support for research projects and clinical trials from Amplo Biotechnology, AMO Pharma, Biogen, Desitin, Fulcrum Therapeutics, GW Pharma, Milo Biotechnology, Pfizer, PTC Therapeutics, Roche, Santhera, Sarepta, Satellos and Ultragenyx. Editor-in-chief for the Journal of Neuromuscular Disease (IOS Press). ANR and EK are employees of and shareholders in Ultragenyx Pharmaceutical Inc.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"141"}}